$17.57
0.11% yesterday
Nasdaq, Nov 25, 09:47 pm CET
ISIN
US6951271005
Symbol
PCRX

Pacira Pharmaceuticals, Inc. Stock price

$17.42
+0.59 3.51% 1M
-12.27 41.33% 6M
-16.32 48.37% YTD
-8.90 33.81% 1Y
-36.83 67.89% 3Y
-28.12 61.75% 5Y
-77.46 81.64% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.13 0.74%
ISIN
US6951271005
Symbol
PCRX
Sector
Industry

Key metrics

Market capitalization $804.34m
Enterprise Value $994.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 5.14
EV/Sales (TTM) EV/Sales 1.43
P/S ratio (TTM) P/S ratio 1.16
P/B ratio (TTM) P/B ratio 1.07
Revenue growth (TTM) Revenue growth 4.40%
Revenue (TTM) Revenue $694.96m
EBIT (operating result TTM) EBIT $102.01m
Free Cash Flow (TTM) Free Cash Flow $193.53m
Cash position $453.81m
EPS (TTM) EPS $-2.05
P/E forward negative
P/S forward 1.16
EV/Sales forward 1.43
Short interest 17.24%
Show more

Is Pacira Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Pacira Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

3x Buy
38%
4x Hold
50%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

Buy
38%
Hold
50%
Sell
13%

Financial data from Pacira Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
695 695
4% 4%
100%
- Direct Costs 236 236
8% 8%
34%
459 459
12% 12%
66%
- Selling and Administrative Expenses 204 204
13% 13%
29%
- Research and Development Expense 77 77
4% 4%
11%
178 178
15% 15%
26%
- Depreciation and Amortization 76 76
13% 13%
11%
EBIT (Operating Income) EBIT 102 102
51% 51%
15%
Net Profit -91 -91
1,400% 1,400%
-13%

In millions USD.

Don't miss a Thing! We will send you all news about Pacira Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pacira Pharmaceuticals, Inc. Stock News

Negative
Seeking Alpha
about 18 hours ago
Pacira BioSciences markets and sells EXPAREL, a non-opioid pain relief therapy. The drug drives revenues of >$500m per annum, but a new generic version has been approved, while Pharma giant Vertex is close to having a similar drug approved. Pacira's share price has plummeted from >$80 in mid-2022 to ~$18 today, as the market sees little growth in the business and notes the competitive threats.
Neutral
Seeking Alpha
19 days ago
Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript
More Pacira Pharmaceuticals, Inc. News

Company Profile

Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Head office United States
CEO Frank Lee
Employees 712
Founded 2006
Website www.pacira.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today